Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
De novo fda approval for a test on worlds biggest killer will be massive!!!
Wait for the herd to arrive spouting shiite
This is a tightly held share when ot moves it rockets.
And not long to wait FDA due in coming days so no sellers down here!
I like this line 'recommendation as the preferred test'
announces that its Risk of Ovarian Cancer Algorithm ("ROCA") test, has received a National Institute for Health and Care Excellence ("NICE") recommendation as the preferred test for OC surveillance in individuals at high risk of ovarian cancer who do not undertake risk reducing surgery.
Is the big one I TRUST THIS COMPANY thats why i have over invested
Great news!
FDA for Cardio test yet to come which will be the big one.
This is great and imo nhs will roll out more areas to geni looking frw .BIT p as saw rns and went to buy but phoned jammed and missed 3.6 thats life if geni get fda i see 12/15p now
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging the release of this announcement on behalf of GENinCode Plc is Matthew Walls, Chief Executive Officer.
GENinCode Plc
("GENinCode" or the "Company")
New NICE Guidance for Ovarian Cancer
Surveillance using the ROCA test is now an option for individuals at high risk of ovarian cancer
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer ("OC"), announces that its Risk of Ovarian Cancer Algorithm ("ROCA") test, has received a National Institute for Health and Care Excellence ("NICE") recommendation as the preferred test for OC surveillance in individuals at high risk of ovarian cancer who do not undertake risk reducing surgery. The new NICE guidance[1] is focused on identifying and managing familial and genetic risk of OC.
Each year in the UK, 7,500 women are diagnosed with OC and over half of those will die from the disease. The risk of developing OC is particularly high in individuals who inherit a known pathogenic variant in certain genes such as BRCA1 or BRCA2. It is estimated that up to 170,000 people in the UK may be carriers of a BRCA gene variant. Identifying such individuals through genetic testing will allow the NHS to better mitigate that risk through prevention and/or surveillance.
Preventative surgery to remove both ovaries and fallopian tubes is the standard of care but where this is not possible, or where the patient decides to delay surgery, NICE now recommends that individuals can be offered surveillance using the ROCA test. The NICE committee reviewed various surveillance protocols, as published in the peer reviewed literature, and concluded that the ROCA test was the most accurate with the best detection rate for earlier stages of OC (stage IIIa or lower). Detection of OC at an earlier stage is associated with a better prognosis and treatment.
The ROCA test uses a proprietary algorithm to calculate a woman's individual OC risk based on several clinical factors including age and accumulating Cancer Antigen 125 (CA-125) blood test results. The ability of the ROCA test to interpret changes in an individual's CA-125 level over time through four monthly interval testing was recognised by the NICE committee as an important contributor to its accuracy and ability to detect OC earlier. Additionally, the NICE committee recognised the published evidence that surveillance using the ROCA test would have a cost-saving benefit for the NHS.
Matthew Walls, Chief Executive Officer of GENinCode Plc, said: "Today's publication of NICE guidance is an important milestone for the ROCA test. After many years of academic and corporate investment, the ROCA test h
Nice
They will move the book up by Tuesday as i put buy order in for 3.5 and would not accept Good luck all
FDA DUE LATE Q1 EARLY Q2 place your bets please!!!!!
FDA approval gets closer and when this stock moves it rockets hold on to yer hats!!!!
Made me add just in case 300000 buyer should do well on that buy . Same old if she drifts will add wanted to wait to april . But the 300000 buyer got my attention
Something stirs big buy news maybe about to drop!
Please sign and share if you would like to force government to debate the issue.
https://petition.parliament.uk/petitions/657294
TO get this down and rubbish volume wont be surprised to see 3p next week
I agree that 12p-15p could be hit very quickly as that would still only put a market cap of about half what it was at IPO i.e at 12p = 21235200 (this includes the recent dilution) and I'm sure it was 40000000 @IPO when we had all the work to be done ahead of us. The BOD also said that they thought they were conservative to comparable peers at the time but wanted to be realistic with the IPO share price. Yes a piece os salt or two required there but still puts todays position a possible future sp uplift into perspective.
Hi swizzydog i dont know he answer to that with these markets . In the past i been in a few awaiting fda approval and most have hit at least 50 percent more some even 100 percent plus . We have little shares here so i stick my neck out and i go for 9/12p thats a guess . Nothing surprises me anymore with shares . LONG term i feel a ten bagger here . Thats why im patience here as it could make a difference if all goes to plan . Willing to buy more but im waiting as 3p could be hit .
Typing error as I meant to say that I don't think it will keep drifting a lot lower before FDA approval.
It is crazy that we are 30% below the last raise when directors bought in at 5p and it is all down to no news which as stated by the RNS has not gone by timescale yet and as far as we all know nothing significant has changed. Anywhere between 3.2p and 3.5p seems very good value in my opinion. I would think that it could just drift a lot lower before time schedules are extended if in deed they ever are going to be. I have always been positive about Geni am so I'm prepared to hold, sit and wait now as it has never been a traders stock on volume alone. Best of luck all holders.
Hi Scoredagainsteps, what are your thoughts on the immediate upside to sp when we get FDA approval? There is nothing to say that a} another news could drop before hand to tickle the sp upwards before FDA news. I was tempted to buy a few @3.5p with a little bit left for April but only so I don't miss the boat lol!. Best of luck with catching the absolute bottom even if it has already come. GLA and DYOR Swissy.
Well soon be 3p what a fool i am buying in to early here . Seems like it dose not pay to invest early these days . A UPDATE would calm the nerves here . Next buy will be at 3p or april what ever comes first .
If they can hit revenue of £2m for year end, I would be quite happy with that.
I did the same . Possible to get up to 13 trusts at 40000 a month nice income there if it happens . A lot happening here hopefully wake up in april. My thinking here if you have shares and can wait to profits etc it could 12/14 bag from this price . I can wait and want to buy more but i do that in april .